STRENGTHENING HUMAN IMMUNITY USING ROBUST ANTIBODY THERAPIES
SparX Biopharmaceutical Corp.
Cure Cancer by Targeting Multiple Pathways with the Right Therapeutic Strategy
SparX Techologies
SAILINGTM
An integrated approach to discovering and building antibodies
SYNMABTM
Design, Selection, Optimization of multi-specific antibodies
SPARX BIFUNCTIONAL ADC PLATFORM
Universally empowering ADCs with high specificity, sensitivity and activity
SparX Capabilities
News
SparX Presents Nab2-ADC, a Groundbreaking Nano Antibody Bifunctional Biparatopic Antibody Drug Conjugate at BIO Asia-Taiwan 2024
Chicago, USA – SparX is thrilled to officially unveil its groundbreaking Nano Antibody Bifunctional Biparatopic Antibody Drug Conjugate (Nab2-ADC), a pioneering development poised to revolutionize
SparX Group Announces First Patient Dosed with SPX-303 Injection, the First in Its Class of anti-LILRB2/PD-L1 Bispecific Antibody Drugs
Chicago, USA – Signifying a monumental step forward in the domain of powered antibody therapies, SparX is thrilled to announce that the first patient has
SparX Biopharmaceutical Announces FDA Greenlight for IND Application of SPX-303, A First-In-Human anti-LILRB2/PD-L1 Antibody Drug
Chicago, USA – Signifying a monumental step forward in the domain of powered antibody therapies, SparX Biopharmaceutical Corp. proudly announces that its Investigational New Drug
The SparX Group Enters into a Collaboration with Arovella Therapeutics for the Development of CLDN18.2-CAR-iNKT Cell Therapy
Chicago, USA – Signifying a monumental step forward in the domain of powered antibody therapies, the SparX Group is thrilled to unveil its strategic alliance
SparX Biopharmaceutical Announces IND Submission to the FDA for Its SPX-303, A First-In-Human anti-LILRB2/PD-L1 Antibody Drug
Chicago, USA – Making significant strides in the domain of powered antibody therapies, SparX Biopharmaceutical Corp. is thrilled to announce its Investigational New Drug (IND)
SPARX BIOPHARMACEUTICAL CORP.
Press Release Sparx Biopharmaceutical Welcomes Dr. Roland Meier as Chief Medical Officer Chicago, USA — Spearheading the field of powered antibody therapies, SparX Biopharmaceutical Corp.
Get in Touch with SparX
- 700 E. Business Center Dr. Mount Prospect, IL 60056
- +1 847 257 7910 (Direct)
- +1 224 580 2979 (extension)
- info@sparxbio.com
